CMPX

Compass Therapeutics, Inc. [CMPX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CMPX Stock Summary

Top 10 Correlated ETFs

CMPX


Top 10 Correlated Stocks

CMPX


In the News

04:00 29 Mar 2024 CMPX

3 Penny Stocks With the Power to 10X Your $1K Investment

Today we will be looking at three penny stocks with the power to 10x your $1K investment. The three firms discussed below have outsized potential to turn a small capital allocation into a much larger return.

01:01 29 Mar 2024 CMPX

Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should Know

Compass Therapeutics, Inc. (CMPX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

11:19 29 Mar 2024 CMPX

Compass Therapeutics, Inc. (CMPX) Loses -28.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Compass Therapeutics, Inc. (CMPX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

08:00 29 Mar 2024 CMPX

Compass Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that the Company will participate in the Piper Sandler 34th Annual Healthcare Conference, which is taking place at the Lotte New York Palace November 29 – December 1, 2022.

08:00 29 Mar 2024 CMPX

Compass Therapeutics to Present at Upcoming Investment Conferences

BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced it will be presenting at the following investor conferences during the month of November 2022.

08:00 29 Mar 2024 CMPX

Compass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference

BOSTON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that the Company will participate in the 24th Annual H.C. Wainwright Global Investment Conference, which is taking place in New York City September 12 – 14, 2022.

08:00 29 Mar 2024 CMPX

Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference

BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced Thomas J. Schuetz, M.D., Ph.D., Co-founder and Chief Executive Officer, is presenting virtually at the 2022 H.C. Wainwright Global Investment Conference, occurring May 23-26th, 2022.

04:01 29 Mar 2024 CMPX

Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009

Call scheduled for Wednesday, May 4, 2022 at 8:00 a.m. ET

09:00 29 Mar 2024 CMPX

Compass Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

BOSTON--(BUSINESS WIRE)---- $CMPX #CMPX--Compass Therapeutics, Inc. (Nasdaq: CMPX) will present a company update at the 40th Annual J.P. Morgan Healthcare Conference on Wed., Jan. 12, 2022.

10:00 29 Mar 2024 CMPX

Compass Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference

BOSTON--(BUSINESS WIRE)---- $CMPX #CMPX--Compass Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference

CMPX Financial details

Company Rating
Neutral
Market Cap
271.55M
Income
-37.51M
Revenue
0
Book val./share
1.26
Cash/share
1.28
Dividend
-
Dividend %
-
Employees
26
Optionable
No
Shortable
Yes
Earnings
21 Mar 2024
P/E
-6.56
Forward P/E
-4.18
PEG
0.86
P/S
-
P/B
1.54
P/C
1.6
P/FCF
-6.31
Quick Ratio
17.94
Current Ratio
18.26
Debt / Equity
0.01
LT Debt / Equity
0.01
-
-
EPS (TTM)
-0.31
EPS next Y
-0.49
EPS next Q
-0.11
EPS this Y
-73.28%
EPS next Y
55.83%
EPS next 5Y
-119.21%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-12.13%
-
-
-
-
SMA20
18.89%
SMA50
25.15%
SMA100
19.55%
Inst Own
53.22%
Inst Trans
0.74%
ROA
-22%
ROE
-22%
ROC
-0.3%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
127.49M
Shs Float
76.11M
-
-
-
-
Target Price
-
52W Range
1.15-3.62
52W High
-31.67%
52W Low
+105%
RSI
53.19
Rel Volume
0.27
Avg Volume
536.1K
Volume
145.34K
Perf Week
-8.89%
Perf Month
40.41%
Perf Quarter
3.54%
Perf Half Y
1.49%
-
-
-
-
Beta
0.571
-
-
Volatility
0.08%, 0.17%
Prev Close
3.54%
Price
2.05
Change
-3.3%

CMPX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.73-0.67-0.96-1.31-0.35
Operating cash flow per share
-0.65-0.61-0.87-0.31-0.32
Free cash flow per share
-0.69-0.62-0.87-0.34-0.33
Cash per share
1.10.491.532.31.77
Book value per share
-1.63-2.281.32.231.73
Tangible book value per share
-1.63-2.281.32.231.73
Share holders equity per share
-1.63-2.281.32.231.73
Interest debt per share
0.30.310.330.070.05
Market cap
442.95M442.95M261.6M199.3M529.09M
Enterprise value
400.19M432.52M223.85M58.82M497.07M
P/E ratio
-11.57-12.75-8.87-2.41-14.38
Price to sales ratio
00000
POCF ratio
-13.15-13.96-9.76-10.13-15.5
PFCF ratio
-12.41-13.75-9.72-9.39-15.41
P/B Ratio
-5.23-3.736.551.422.91
PTB ratio
-5.23-3.736.551.422.91
EV to sales
00000
Enterprise value over EBITDA
-11.2-13.87-8.84-1.99-13.29
EV to operating cash flow
-11.88-13.63-8.35-2.99-14.57
EV to free cash flow
-11.21-13.43-8.32-2.77-14.48
Earnings yield
-0.09-0.08-0.11-0.41-0.07
Free cash flow yield
-0.08-0.07-0.1-0.11-0.06
Debt to equity
-0.17-0.130.230.030.02
Debt to assets
0.230.490.180.030.01
Net debt to EBITDA
1.20.331.494.740.86
Current ratio
6.962.674.9713.8412.05
Interest coverage
-49.95-27.73-30.63-221.3-17.65
Income quality
0.880.910.910.240.87
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.060.0100.080.01
Capex to revenue
00000
Capex to depreciation
-1.05-0.22-0.04-0.97-0.11
Stock based compensation to revenue
00000
Graham number
5.195.845.298.113.69
ROIC
0.550.33-0.56-0.56-0.21
Return on tangible assets
-0.59-1.14-0.57-0.54-0.18
Graham Net
-1.76-2.371.142.081.6
Working capital
50.42M16.42M40.1M136.47M178.62M
Tangible asset value
-84.77M-118.6M39.95M140.08M181.64M
Net current asset value
-90.52M-122.75M38.24M133.43M176.78M
Invested capital
-0.17-0.130.230.030.02
Average receivables
00000
Average payables
01.18M845K964K2.12M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
0108.29161.09194.86648.34
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
03.372.271.870.56
Inventory turnover
00000
ROE
0.450.29-0.74-0.59-0.2
Capex per share
-0.04-0.010-0.020

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.11-0.1-0.05-0.09-0.08
Operating cash flow per share
-0.11-0.1-0.1-0.08-0.05
Free cash flow per share
-0.11-0.1-0.1-0.08-0.05
Cash per share
1.191.771.391.331.28
Book value per share
1.151.731.391.331.26
Tangible book value per share
1.151.731.391.331.26
Share holders equity per share
1.151.731.391.331.26
Interest debt per share
0.040.040.010.020.02
Market cap
230.3M529.09M413.25M403M251.03M
Enterprise value
217.04M497.07M388.86M386.06M222.64M
P/E ratio
-5.07-12.84-17.33-8.93-6.3
Price to sales ratio
00000
POCF ratio
-21.05-49.72-33.79-39.85-42.39
PFCF ratio
-21-49.47-33.79-39.81-42.32
P/B Ratio
1.982.912.362.391.57
PTB ratio
1.982.912.362.391.57
EV to sales
00000
Enterprise value over EBITDA
-18.89-44.74-42.13-30.02-19.43
EV to operating cash flow
-19.84-46.71-31.8-38.18-37.6
EV to free cash flow
-19.79-46.48-31.8-38.13-37.53
Earnings yield
-0.05-0.02-0.01-0.03-0.04
Free cash flow yield
-0.05-0.02-0.03-0.03-0.02
Debt to equity
0.030.020.020.010.01
Debt to assets
0.030.010.010.010.01
Net debt to EBITDA
1.152.882.641.322.48
Current ratio
12.812.0516.4118.0718.26
Interest coverage
-20.22-9.965.1800
Income quality
0.910.921.560.90.59
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00.01000
Capex to revenue
00000
Capex to depreciation
-0.06-0.110-0.02-0.02
Stock based compensation to revenue
00000
Graham number
1.71.951.211.631.49
ROIC
-0.1-0.06-0.04-0.08-0.07
Return on tangible assets
-0.09-0.05-0.03-0.06-0.06
Graham Net
1.081.61.291.251.21
Working capital
112.98M178.62M172.41M165.57M157.46M
Tangible asset value
116.12M181.64M175.27M168.29M160.05M
Net current asset value
110.83M176.78M170.89M164.38M156.59M
Invested capital
0.030.020.020.010.01
Average receivables
00000
Average payables
4.65M3.07M2.25M924.5K1.52M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
510.25628.88210.5137.18445.36
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.180.140.430.660.2
Inventory turnover
00000
ROE
-0.1-0.06-0.03-0.07-0.06
Capex per share
00000

CMPX Frequently Asked Questions

What is Compass Therapeutics, Inc. stock symbol ?

Compass Therapeutics, Inc. is a US stock , located in Boston of Ma and trading under the symbol CMPX

What is Compass Therapeutics, Inc. stock quote today ?

Compass Therapeutics, Inc. stock price is $2.05 today.

Is Compass Therapeutics, Inc. stock public?

Yes, Compass Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap